Prosecution Insights
Prosecution Insights
8 pending office actions • 5 clients • 8 examiners • 7 art units • 0 of 8 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (75%) |
| §102 only | 1 (12%) |
| No statute on record | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAMBY, RICHARD M | 1 | 89.2% | +6.4% |
| LIPPERT, JOHN WILLIAM | 1 | 55.7% | +42.6% |
| GROUX, JENNIFER LILA | 1 | 35.6% | +46.3% |
| NGUYEN, JOHN P | 1 | 44.5% | +41.6% |
| MCLEOD, AFRICA MHAIRIE | 1 | 44.7% | +68.6% |
| COUGHLIN, DANIEL F | 1 | 39.2% | +20.0% |
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 54.1% | +20.8% |
| DRAPER, LESLIE A ROYDS | 1 | 27.4% | +43.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18801045 | Canopy For Climate And Solar Mitigation | CAMBY, RICHARD M | 22d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17274726 | Use of CFTR Modulators For Treating Cerebrovascular Conditions | DRAPER, LESLIE A ROYDS | 66d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17274773 | Use of Casein Kinase 1 Inhibitors For Treating Vascular Diseases | RAMOS LEWIS, JOSMALEN MILAGROS | 85d overdue |
| 17783818 | Dot Printing Method And Device For Additive Manufacturing Of Dosage Forms Which Contain Active Substances | GROUX, JENNIFER LILA | 73d overdue |
| 17274726 | Use of CFTR Modulators For Treating Cerebrovascular Conditions | DRAPER, LESLIE A ROYDS | 66d overdue |
| 18258742 | Method For Producing Patient-Optimised Dosage Forms | LIPPERT, JOHN WILLIAM | 60d overdue |
| 17639113 | Minimal Messenger RNAs and uses thereof | MCLEOD, AFRICA MHAIRIE | 19d overdue |
| 18001582 | Pharmaceutical Compositions Containing Enterokine Releasing Substances In Multiple Dosage Forms In Combination With Gelling Agents | NGUYEN, JOHN P | 9d |
| 17615559 | Polyvalent Dosage Forms and Method For Their Production | COUGHLIN, DANIEL F | 40d |
| Client (Assignee) | Pending OAs |
|---|---|
| DiHeSys Digital Health Systems | 3 |
| Qanatpharma AG | 2 |
| Vandewater Capital Holdings, LLC | 1 |
| APHAIA IP AG | 1 |
| University of Zurich | 1 |
| Art Unit | Apps |
|---|---|
| 1619 | 2 |
| 3661 | 1 |
| 1615 | 1 |
| 1754 | 1 |
| 1635 | 1 |
| 1621 | 1 |
| 1629 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18801045 | Canopy For Climate And Solar Mitigation | Vandewater Capital Holdings, LLC | CAMBY, RICHARD M | 3661 | §103 | Non-Final OA | 22d overdue | Pending | Aug 12, 2024 |
| 18258742 | Method For Producing Patient-Optimised Dosage Forms | Dihesys Digital Health Systems GmbH | LIPPERT, JOHN WILLIAM | 1615 | §103 | Non-Final OA | 60d overdue | Pending | Oct 12, 2023 |
| 17783818 | Dot Printing Method And Device For Additive Manufacturing Of Dosage Forms Which Contain Active Substances | Dihesys Digital Health Systems GmbH | GROUX, JENNIFER LILA | 1754 | §103 | Non-Final OA | 73d overdue | Pending | Dec 14, 2022 |
| 18001582 | Pharmaceutical Compositions Containing Enterokine Releasing Substances In Multiple Dosage Forms In Combination With Gelling Agents | Aphaia Ip AG | NGUYEN, JOHN P | 1619 | §103 | Final Rejection | 9d | Pending | Dec 12, 2022 |
| 17639113 | Minimal Messenger RNAs and uses thereof | UNIVERSITAET ZUERICH | MCLEOD, AFRICA MHAIRIE | 1635 | Other | Non-Final OA | 19d overdue | Pending | Feb 28, 2022 |
| 17615559 | Polyvalent Dosage Forms and Method For Their Production | Dihesys Digital Health Systems GmbH | COUGHLIN, DANIEL F | 1619 | §103 | Non-Final OA | 40d | Pending | Nov 30, 2021 |
| 17274773 | Use of Casein Kinase 1 Inhibitors For Treating Vascular Diseases | Qanatpharma AG | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103 | Non-Final OA | 85d overdue | Pending | Mar 09, 2021 |
| 17274726 | Use of CFTR Modulators For Treating Cerebrovascular Conditions | Qanatpharma AG | DRAPER, LESLIE A ROYDS | 1629 | §102 | Final Rejection | 66d overdue | Pending | Mar 09, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial